Sustained in vitro interferon-beta release and in vivo toxicity of PLGA and PEG-PLGA nanoparticles

Interferon-beta-1a (IFN-β-1a) can diminish the symptoms of relapsing-remitting multiple sclerosis. Herein, we prepared sustained drug delivery IFN-β-1a-loaded nanoparticles by a double emulsion solvent evaporation method. Bovine serum albumin (BSA) model drug was used to optimize the preparation of...

Full description

Saved in:
Bibliographic Details
Published in:RSC advances 2020-04, Vol.10 (27), p.15893-15900
Main Authors: Fodor-Kardos, Andrea, Kiss, Ádám Ferenc, Monostory, Katalin, Feczkó, Tivadar
Format: Article
Language:English
Subjects:
Biocompatibility
Chemistry
Drug delivery systems
Glycolic acid
In vivo methods and tests
Interferon
Multiple sclerosis
Nanoparticles
Optimization
Polymers
Serum albumin
Toxicity
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Interferon-beta-1a (IFN-β-1a) can diminish the symptoms of relapsing-remitting multiple sclerosis. Herein, we prepared sustained drug delivery IFN-β-1a-loaded nanoparticles by a double emulsion solvent evaporation method. Bovine serum albumin (BSA) model drug was used to optimize the preparation of nanoparticles composed of four types of poly(lactic- -glycolic acid) (PLGA) polymers and two pegylated PLGA (PEG-PLGA) polymers. optimization, selected PLGA and PEG-PLGA polymers were able to entrap IFN-β-1a with high encapsulation efficiency (>95%) and low size (145 nm and 163 nm, respectively). release kinetics of BSA and IFN-β showed similar tendency for PLGA and PEG-PLGA nanoparticles, respectively. Although the drug loaded nanoparticles did not show toxicity in hepatocyte cells, mild toxic effects such as pale kidney and pyelectasis were observed in the studies.
ISSN:2046-2069
2046-2069
DOI:10.1039/c9ra09928j